WallStSmart

ASML Holding NV ADR (ASML)vsAstraZeneca PLC (AZN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 80% more annual revenue ($58.74B vs $32.67B). ASML leads profitability with a 29.4% profit margin vs 17.4%. AZN appears more attractively valued with a PEG of 1.50. AZN earns a higher WallStSmart Score of 66/100 (B-).

ASML

Buy

56

out of 100

Grade: C

Growth: 6.0Profit: 9.5Value: 7.3Quality: 5.0

AZN

Strong Buy

66

out of 100

Grade: B-

Growth: 6.7Profit: 8.0Value: 10.0Quality: 6.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASMLSignificantly Overvalued (-194.2%)

Margin of Safety

-194.2%

Fair Value

$518.82

Current Price

$1399.42

$880.60 premium

UndervaluedFair: $518.82Overvalued
AZNUndervalued (+32.8%)

Margin of Safety

+32.8%

Fair Value

$306.07

Current Price

$185.78

$120.29 discount

UndervaluedFair: $306.07Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ASML5 strengths · Avg: 9.8/10
Market CapQuality
$517.23B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
50.5%10/10

Every $100 of equity generates 51 in profit

Operating MarginProfitability
35.3%10/10

Strong operational efficiency at 35.3%

Free Cash FlowQuality
$10.57B10/10

Generating 10.6B in free cash flow

Profit MarginProfitability
29.4%9/10

Keeps 29 of every $100 in revenue as profit

AZN5 strengths · Avg: 9.0/10
Market CapQuality
$284.63B10/10

Mega-cap, among the largest globally

EPS GrowthGrowth
53.9%10/10

Earnings expanding 53.9% YoY

Return on EquityProfitability
22.8%9/10

Every $100 of equity generates 23 in profit

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$1.38B8/10

Generating 1.4B in free cash flow

Areas to Watch

ASML4 concerns · Avg: 3.0/10
PEG RatioValuation
2.204/10

Expensive relative to growth rate

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

P/E RatioValuation
46.5x2/10

Premium valuation, high expectations priced in

Price/BookValuation
23.7x2/10

Trading at 23.7x book value

AZN3 concerns · Avg: 3.3/10
P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.1%4/10

4.1% revenue growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ASML

The strongest argument for ASML centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 29.4% and operating margin at 35.3%.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.

Bear Case : ASML

The primary concerns for ASML are PEG Ratio, Revenue Growth, P/E Ratio. A P/E of 46.5x leaves little room for execution misses.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

ASML carries more volatility with a beta of 1.43 — expect wider price swings.

ASML is growing revenue faster at 4.9% — sustainability is the question.

ASML generates stronger free cash flow (10.6B), providing more financial flexibility.

Monitor SEMICONDUCTOR EQUIPMENT & MATERIALS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AZN scores higher overall (66/100 vs 56/100), backed by strong 17.4% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ASML Holding NV ADR

TECHNOLOGY · SEMICONDUCTOR EQUIPMENT & MATERIALS · USA

ASML Holding NV develops, produces, markets, sells and services advanced semiconductor equipment systems consisting of lithography, metrology and inspection related systems for memory and logic chip manufacturers. The company is headquartered in Veldhoven, the Netherlands.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?